|drug801||Cognitive Behavioral Brief-Telepsychotherapy Wiki||1.00|
|drug523||Brief Interpersonal Telepsychotherapy Wiki||1.00|
There is one clinical trial.
The study consists in a pragmatic superiority randomized controlled trial comparing different strategies of psychotherapy for professionals and students from essential services with high levels of emotional distress during the COVID-19 pandemic in Brazil. Therapeutic strategies to be evaluated are Brief Cognitive Behavioral Telepsychotherapy, Brief Interpersonal Telepsychotherapy and Telepsychoeducation, as an active control. Note: This study was approved by the Ethics and Research Committee of the Hospital de Clínicas de Porto Alegre and is originally registered at Plataforma Brasil, a Brazilian study registration platform (under CAAE: 30608420.5.0000.5327). Recruitment began in May 28th 2020.
Description: Proportion of participants with a 50% reduction in T-scores at 1-month in the scales Patient-Reported Outcomes Measurement Information System (PROMIS) of Depression, Anxiety and Anger that were scored above 70 at baseline.Measure: Symptom Reduction at 1-month Time: 1-month
Description: Proportion of participants with a 50% reduction in T-scores at 3 and 6-months follow-up in the scales Patient-Reported Outcomes Measurement Information System (PROMIS) of Depression, Anxiety and Anger that were scored above 70 at baseline measuredMeasure: Symptom Reduction at 3 and 6-months follow-up Time: 3 and 6-month
Description: Remission levels (proportion of patients with T-score of 50 or below) in distress scales (PROMIS of Depression, Anxiety and Anger)Measure: Remission Levels in distress scales Time: 1, 3 and 6-months
Description: Service satisfaction measured by the net-promoter score at the end of the treatment (proportion of promoters - scores of 9 or 10)Measure: Service Satisfaction Time: 1-month
Description: Mean score change in quality of life scale (PROMIS General Life Satisfaction Scale or GLSS)Measure: Improvement in Quality of Life Time: 1, 3 and 6-months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports